Abstract

Rat sialorphin (Gln-His-Asn-Pro-Arg) is a natural blocker of neprilysin (NEP) that belongs to the family of endogenous opioid peptide-degrading enzymes. Studies have confirmed the efficiency of sialorphin in blocking the activity of NEP, both in vitro and in vivo. It has been demonstrated that this inhibitor has a strong analgesic, anti-inflammatory, immunological and metabolic effect either directly or indirectly by affecting the level of Met/Leu-enkephalins. In this work, sialorphin and their 12 analogues were synthesised using the solid-phase method. The effect of the peptides on the degradation of Met-enkephalin by NEP and metabolic degradation in human plasma was investigated in vitro. We show that the change in the N-terminal amino acid configuration from l to d in almost all peptides, except d-Arg-His-Asn-Pro-Arg (peptide XI), led to the abolition of their inhibitory activity. With molecular modelling technique we explained the structural properties of the l and d-arginine located on the N-terminal part of the peptide. The detailed analysis of the protein binding pocket allowed us to explain why d-arginine is so unique among all d residues. Peptide XI showed the highest stability among the tested peptides in human plasma. For instance sialorphin after a 2-hour incubation in human plasma was almost completely decomposed, while the level of peptide XI dropped to 45% after 48 h under these conditions.

Highlights

  • There are three types of opioid receptors in mammalian tissues, namely mu, kappa, and delta ones (MOR, KOR, and DOR, respectively)

  • The peptidases involved in the degradation of enkephalins in human plasma are not necessarily similar from those involved in tissue synaptic spaces

  • The peptides modified in the first position with I­le1, V­ al1, ­Lys1, and ­Leu1 displayed a higher inhibitory potency for NEP as compared to that of sialorphin

Read more

Summary

Introduction

There are three types of opioid receptors in mammalian tissues, namely mu, kappa, and delta ones (MOR, KOR, and DOR, respectively) They have been known to be involved in pain signaling pathways and their exogenous ligands have been used in the treatment of. Endogenous opioid receptor ligands Met-enkephalin (TyrGly-Gly-Phe-Met) and Leu-enkephalin (Tyr-Gly-Gly-PheLeu) share similar biological properties with their exogenous counterparts including antinociception and the regulation of GI motility, secretion, proliferation, and immune functions (Mosińska et al 2016). They are rapidly destroyed and their pharmacological action is dissipated. DPP III activity gives two minor metabolites: Tyr-Gly and Gly-Phe-Met (Roques et al 1993)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call